| Gene symbol | TNF | Synonyms | DIF, TNF-alpha, TNFA, TNFSF2, TNLG1F | Type of gene | protein-coding |
| Chromosome | 6 | Map location | 6p21.33 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | tumor necrosis factor | ||||
| GTO ID | GTC1231 |
| Trial ID | NCT00126724 |
| Disease | Ankylosing Spondylitis | Rheumatoid Arthritis | Psoriatic Arthritis |
| Altered gene | TNF |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | Gene transfer |
| Treatment | tgAAC94 |
| Phase | Phase1|Phase2 |
| Recruitment status | Completed |
| Title | A Phase I/II Study of Repeat Intra-articular Administration of tgAAC94, a Recombinant Adeno-Associated Vector Containing the TNFR:Fc Fusion Gene, in Inflammatory Arthritis Subjects With and Without Concurrent TNF-alpha Antagonists |
| Year | 2005 |
| Country | United States |
| Company sponsor | Targeted Genetics Corporation |
| Other ID(s) | 13G01|NIH Protocol Number: 0504-705 |
| Vector information | |||||||||
|
|||||||||
| Cohort1: dose level 1 | |||||||||
|
|||||||||
| Cohort2: dose level 2 | |||||||||
|
|||||||||
| Cohort3: dose level 3 | |||||||||
|
|||||||||